In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Tyco, CR Bard to merge; deal terminated

Executive Summary

Tyco International had planned to acquire CR Bard (vascular, urological, and oncological diagnosis and intervention products) in a stock swap worth about $3.2bn, including the assumption of debt. However, since Tyco announced it will split into four independent companies, CR Bard and Tyco have mutually agreed to terminate their merger agreement. No break-up fees will be incurred.
Deal Industry
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Surgical Equipment & Devices
    • Therapeutic Equipment & Devices
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock

Related Companies

Advertisement
UsernamePublicRestriction

Register